Moderna Jumps 150% as Cramer Calls Stock Investable Again on Pipeline, Profitability Plan
Updated
Updated · CNBC · Jul 1
Moderna Jumps 150% as Cramer Calls Stock Investable Again on Pipeline, Profitability Plan
1 articles · Updated · CNBC · Jul 1
Summary
Moderna has rallied nearly 150% this year, and Jim Cramer said the stock is "investable again" as the company finally shows a clearer post-Covid growth story.
Science Day presentations last week outlined a 10-year roadmap built around a broader pipeline and a path to profitability, helping drive another roughly 20% gain since then.
Cancer programs stood out most: Moderna has mid- and late-stage trials in melanoma, non-small cell lung cancer, renal cell carcinoma and bladder cancer, with late-stage melanoma data due later this year for Intismeran plus Merck's Keytruda.
Regulatory progress is also building outside oncology, with an FDA advisory panel backing Moderna's flu shot ahead of an Aug. 5 decision and the European Commission already approving its combined Covid-flu vaccine.
Even after the surge, the shares remain far below their $484 pandemic-era peak, and Cramer urged investors to wait for a pullback because the turnaround could still take years.